Last reviewed · How we verify
NCT06864182
Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
Phase 1 trial testing CX2101A tablet in COVID-19 in 60 participants. Completed in 25 May 2024.
25 May 2024
Quick facts
| Lead sponsor | Heronova Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 21 March 2024 |
| Primary completion | 25 May 2024 |
| Estimated completion | 25 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CX2101A tablet — full drug profile →
- CX2101A placebo tablet
- CX2101A enteric-coated tablet — full drug profile →
- CX2101A placebo enteric-coated tablet
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Coronavirus Infection — all drugs for Coronavirus Infection →
Sponsor
Heronova Pharmaceuticals — full company profile →
Who can join
Adults 18 to 55, any sex, with COVID-19 or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and enteric-coated tablets; and a multiple ascending dose (MAD) study of CX2101A tablets. The BA study (100 mg) is integrated into the SAD study(Nested within the SAD protocol to optimize resource utilization).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06864182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Heronova Pharmaceuticals trials
Trials by the same sponsor.
- NCT07417566 — A Study of DC6001 Tablet in Healthy Chinese Adult Subjects · Phase 1 · recruiting
- NCT07071090 — A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
- NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
- NCT06873542 — A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06864182 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heronova Pharmaceuticals
- Last refreshed: 14 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06864182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing